Curasight
Curasight Q3: Ready to increase momentum for the platform - SEB (SEB Research)

2021-11-25 09:52

Curasight has reported its Q3/21 quarterly report. The financial P&L is not of great importance for an upcoming biotech company, but it is encouraging to see Curasight being well capitalised, as new funding was secured during the quarter. By year-end, we expect the company to have more than DKK 70m in cash. Curasight is therefore well positioned to accelerate its plans for uTREAT (therapy) and uTRACE (diagnostic) further, in our view.

SEB Research

This research has been commissioned by the company. Only for professional investors resident in EEA member states. Reports may not be distributed to the US or other jurisdictions where to do so would be unlawful. Please see the disclaimer tab for any details of investment banking services recently provided by SEB that could be considered relevant to the subject matter of this research.


redaktion@finwire.org
© Copyright

Curasight - I dag

{point.key}

Marknadsöversikt

Stockholmsbörsen, OMXS30

I dag
-
Senast
-
{point.key}

Världsindex

Index +/- % Senast
DAX - -
Hang Seng - -
Nikkei - -

Valutor

Valuta +/- % Senast
USD/SEK - -
EUR/SEK - -
GBP/SEK - -
EUR/USD - -

Räntor

Ränta +/- % Senast
5-års ränta - -
10-års ränta - -

Råvaror

Råvara +/- % Senast
Guld - -
Silver - -
Koppar - -